We have previously demonstrated that the deathassociated protein kinase 2 (DAPK2) expression is significantly reduced in acute myeloid leukemia (AML), particularly in acute promyelocytic leukemia (APL) blast cells. In this study, we aimed at further understanding DAPK2 function and regulation during arsenic trioxide (ATO) cytotoxic or all-trans retinoic acid (ATRA) differentiation therapy in APL cells. We found that the p53 family member transactivation domain-p73 isoform (TAp73) binds to and activates the DAPK2 promoter, whereas the dominant-negative DNp73 isoform inhibits DAPK2 transcription. Furthermore, the knocking down of tumor protein p73 (TP73) in NB4 cells resulted in reduced DAPK2 expression associated with decreased cell death and autophagy upon ATO and ATRA treatment, respectively. Moreover, the silencing of DAPK2 revealed that DAPK2 is an important downstream effector of p73 in ATO-induced apoptosis but not autophagy responses of APL cells. In contrast, the p73-DAPK2 pathway is essential for ATRA-induced autophagy that is mediated by an interaction of DAPK2 with the key autophagy-related protein (ATG)5. Lastly, we show that DAPK2 binds and stabilizes the p73 protein; thus, we propose a novel mechanism by which ATO-or ATRA-induced therapy responses initiate a positive p73-DAPK2 feedback loop.
Introduction
APL is characterized by a translocation involving the RARA gene and genes encoding for aggregate prone proteins [1, 2] . The most frequent translocation, t (15;17) involves the PML gene and leads to the expression of the oncofusion protein PML-RARA. PML-RARA confers a differentiation arrest at the promyelocytic stage and contributes to increased self-renewal and to the antiapoptotic phenotype of leukemic blast cells [3] . APL t(15;17) is successfully treated with differentiation therapy using ATRA in combination with chemotherapy or ATO to target the leukemic stem cells [3] . ATO, as a single agent, represents an effective treatment in certain APL patients [4] and therefore, was integrated in frontline therapy for APL patients [5] . ATO inhibits neoplastic cell growth by inducing cell-cycle arrest and TP73-dependent apoptosis in PML-RARA-positive APL cells [6] [7] [8] . Both ATRA and ATO treatment leads to degradation of aggregated PML-RARA by autophagy [9] [10] [11] . Autophagy is a selfdegradation process characterized by the formation of doublemembraned vesicles, so-called autophagosomes, which engulf cytoplasmic contents [12] . Autophagosomes then fuse with lysosomes, allowing the degradation and recycling of their contents. At basal level activity, autophagy mainly functions as a homeostatic mechanism to prevent accumulation of superfluous or defective metabolites and organelles. Under stressful conditions, such as starvation or particular cytotoxic therapies, autophagy supports cell survival [12] .
P73 belongs to the p53 family of transcription factors regulating key cellular functions, such as cell death, autophagy, and cell cycle. Unlike p53, p73 is rarely mutated in cancer, but its expression is frequently deregulated [13] . Indeed, AML patients show frequent TP73 promoter hypermethylation associated with decreased p73 expression [14, 15] . p73 exists as multiple protein isoforms as a result of alternative splicing events and the existence of an alternative promoter [16] . The two alternative promoters allow the generation of full-length TAp73 and truncated DNp73, containing or lacking an N-terminal TA, respectively. Whereas TAp73 induces cell-cycle arrest and apoptotic cell death, DNp73 inhibits both p53 and TAp73 transactivation activities by forming heterotetramers [17] . Of note, several reports describe a residual transactivation potential of DNp73a isoforms, allowing the transcriptional activation of particular downstream targets [18] [19] [20] . Moreover, p73 positively modulates autophagy [21] via direct transcriptional regulation of ATG-related genes, such as ATG5 and DRAM-1 [21, 22] , both essential for ATRA-induced APL differentiation [10, 23] .
DAPK2 is a member of the serine-threonine kinase DAPK family, including its closest homolog, DAPK1. To date, several reports describe a role for DAPK2 in TRAIL-, TNF-a/FAS receptor-, E2F1-, or epigallocatechin-3-gallate-mediated cell death [24] [25] [26] [27] [28] , as well as in autophagy, by increasing LC3 dot formation and regulating mammalian target of rapamycin phosphorylation [29] [30] [31] . Within the human hematopoietic system, DAPK2 is predominantly expressed in neutrophil and eosinophil cells, whereas DAPK1 and -3 are mainly expressed in monocytes [32] . In line with these expression patterns, previous work in our laboratory demonstrated a critical role of DAPK2 in granulocytic differentiation [33, 34] . Furthermore, we found that DAPK2 mRNA levels are reduced significantly in primary AML blasts, particularly in APL, where PML-RARA directly inhibits DAPK2 transcription [34] .
In the present study, we aimed to deepen our knowledge of DAPK2 transcriptional regulation and function during AML therapy. We demonstrate that TAp73 positively regulates DAPK2 transcription and that DAPK2 is essential for efficient p73-dependent apoptosis but not for autophagy mediated by ATO. On the other hand, we show that p73 protein stability is partially dependent on DAPK2 kinase activity, creating a positive-feedback loop in response to ATO or ATRA in APL cells. Lastly, DAPK2 is required for ATRA-induced autophagy via binding to ATG5.
MATERIALS AND METHODS

Cell lines and culture conditions
The human APL cell lines, HT93 and NB4, were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany). Both cell lines were maintained in RPMI 1640 with 10% FCS, 50 U/ml penicillin, and 50 mg/ml streptomycin in a 5% CO 2 -95% airhumidified atmosphere at 37°C. For ATO experiments, NB4 or HT93 cells were treated with 1, 2.5, or 5 mM ATO (dissolved in water) for 24 h.
293T cells were maintained in DMEM (Sigma-Aldrich, St. Louis, MO, USA), supplemented with 5% FBS, 1% penicillin/streptomycin, and 1% Hepes (Sigma-Aldrich), and kept in a 7.5% CO 2 -95% air-humidified atmosphere at 37°C. The human nonsmall cell lung cancer cell line H1299 was maintained in RPMI 1640 with 10% FCS, 50 U/ml penicillin, and 50 mg/ml streptomycin in a 5% CO 2 -95% air-humidified atmosphere at 37°C.
ChIP
ChIP assays were done according to the ChIP protocol (Activ Motif, Carlsbad, CA, USA) using chromatin from H1299 cells transiently transfected with a plasmid expressing HA-tagged TA73b or EGFP and using anti-HA antibody (sc-7392x; Santa Cruz Biotechnology, Dallas, TX, USA). Following DNA purification, PCR was performed using a JumpStart Taq (Sigma-Aldrich) and the following primers for DAPK2 p21 CIP1 (CDKN1A) 
Reporter assays and transient transfections
The DAPK2 promoter constructs used in this study have been described earlier [27] . H1299 cells were transfected with lipofectamine (Thermo Fisher Scientific, Zug, Switzerland), according to the manufacturer's protocol. In brief, cells were transfected with 40 ng reporter, 40 ng effector, and 5 ng plasmid for Renilla luciferase-thymidine kinase expression (Promega AG, Dübendorf, Switzerland). Reporter expression was analyzed using the DualGlo Luciferase Reporter Assay System (Promega). Firefly luciferase activity of each sample was normalized to its Renilla luciferase activity, and the fold activation was obtained by setting the value of empty vector control to 1.0.
Real-time qPCR
Total RNA was extracted using the miRCURY RNA Isolation kit, according to the manufacturer's protocol (Exiqon, Vedbaek, Denmark). Total RNA was reverse transcribed using random primers (Roche Diagnostics, Basel, Switzerland) and Moloney murine leukemia virus RT (Promega). qPCR was performed using the ABI PRISM 7700 Sequence Detection System (Thermo Fisher Scientific, Rotkreuz, Switzerland). For quantification of DAPK2 mRNA, the TaqMan Gene Expression Assay Hs00204888_m1 (Thermo Fisher Scientific) was used. HMBS and TP73 primers and probes have been described earlier [17, 36] . Changes (n-fold) were calculated using the 2-DDCT method of relative quantification.
Cell lysate preparation and Western blotting
Whole-cell extracts were prepared using urea lysis buffer, and 30-60 mg total protein was loaded on a 12% denaturing polyacrylamide self-cast gel (Bio-Rad Laboratories, Hercules, CA, USA). Blots were incubated with the primary antibodies in 0.05% TBST/5% milk overnight at 4°C, incubated with HRPcoupled secondary goat anti-rabbit and goat anti-mouse antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:5-10,000 for 1 h at room temperature. Primary antibodies used were anti-DAPK2 (2323; ProSci Inc., Poway, CA, USA), anti-cleaved caspase 3 (#9661; Cell Signaling Technology), anti-ATG5 (#2630; Cell Signaling Technology), and anti-LC3B (NB600-1384; Novus Biologicals, Littleton, Colorado, USA). (FLAGIPT1; Sigma-Aldrich). In brief, cells were lysed on the dish using lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100), supplemented with protease inhibitors (cOmplete; Roche Diagnostics); the lysates were collected and centrifuged, and the supernatant was collected. Crude protein lysate (1.5 mg) was incubated with 40 ml FLAG M2 beads overnight at 4°C, and then beads were spun down and washed before eluting in 2 times sample buffer and loaded on an SDS-PAGE gel.
Lentiviral vectors
Caspase 3/7 activity
Caspase 3/7 activation was measured using the Caspase-Glo 3/7 Assay, according to the manufacturer's protocol (Promega). Values obtained were normalized to control untreated cells.
Viability assays
Cells were seeded in flat-bottom, 96-well culture plates at a density of 2 3 10 4 cells/well. Cells were treated with ATO (1, 2.5, or 5 mM). The plates were incubated at 37°C and 5% CO 2 for 24 h. alamarBlue (10 ml) was added to each well, and the plates were incubated for 4 h before absorbance was measured at 590 and 630 nm. Growth medium was used as a reference (Abs0 Immunofluorescence microscopy Cells were prepared as described previously [38] . In brief, cells were fixed with ice-cold 100% methanol for 4 min and then washed with PBS containing 0.5% glycine. Anti-LC3B (3868; Cell Signaling Technology) antibody was incubated for 1 h at room temperature, followed by washing steps with PBS-T. Cells were incubated with the secondary antibody (anti-rabbit, 111-096-045; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) for 1 h at room temperature. Prior mounting in fluorescence mounting medium (S3032; Agilent, Santa Clara, CA. USA) cells was washed 3 times with PBS-T. Images were taken on a confocal microscope FLUOVIEW FV1000 (Olympus, Volketswil, Switzerland) at 363 magnification.
Autophagic flux analysis by flow cytometry 
Statistical analysis
Nonparametric Mann-Whitney U tests were applied to compare the difference between two groups using Prism software. P , 0.05 was considered statistically significant.
RESULTS
P73 directly regulates DAPK2 transcription
By analyzing DAPK2 expression in AML samples using the BloodSpot gene-expression profiles database [40], we could further confirm our earlier data showing that DAPK2 mRNA levels are significantly lower in AML compared with a healthy granulocyte with particular low levels in APL blasts [34] (Supplemental Fig. 1 ). To unravel the mechanisms accounting for the low DAPK2 mRNA levels found in AML blasts, we aimed at identifying new DAPK2 transcriptional regulators. As TAp73 is frequently down-regulated in AML, as a result of hypermethylation and functions in AML blast differentiation [14, 15 , 41], we tested whether the DAPK2 promoter contains putative p73 binding sites. With the use of MatInspector 8.0 software, we identified a putative p53 family binding site at position 21056 bp upstream of the transcriptional start site in the DAPK2 promoter (Fig. 1A) . To verify binding of TP73 to this site, we performed ChIP assays using 293T cell lysates expressing HA-tagged TAp73b or EGFP as a negative control for the HA-IP. Anti-H3) and IgG pulldowns were used as positive and negative controls, respectively. Precipitated chromatin was used to amplify a 188 bp (-1056) fragment of the DAPK2 promoter containing the putative p73 binding site. In addition, we amplified a region in the CDKN1A promoter containing a known p53/p73 binding site as a positive control [42] . As expected, TAp73b binds to the CDKN1A promoter (Fig. 1B, right) . Moreover, we detected in vivo binding of TAp73b to the -1056 p73 binding site in the DAPK2 promoter in two independent ChIP assays ( Fig. 1B, right) . Unspecific binding to the DAPK2 promoter was not seen in the EGFP-transfected cells (Fig. 1B, left) . Next, to test whether the different p73 isoforms activate the DAPK2 promoter, we used a 2.1 kb DAPK2 promoter reporter construct containing the putative p53-responsive element and cotransfected it together with different p73 isoform expression plasmids (TAp73a, TAp73b, or DNp73a) in H1299 cells. The TAp73b is more stable than TAp73a, as it lacks the sterile a motif domain, resulting in a more robust activation of TP73 transcriptional targets. In addition, we included a p73a DNA binding mutant (TAp73a_R292H) as a negative control. The TAp73a_ R292H mutation abolishes DNA binding activity of TAp73 with Total protein (Tot. Prot.) was extracted and subjected to immunoblotting using anti-DAPK2 antibody. Total protein is shown as loading control. The relative protein expressions were normalized to total protein and quantified using ImageJ software (NIH, Bethesda, MD, USA) and shown in histogramm as adjusted relative density. (D) DAPK2 mRNA levels were determined by qPCR and analyzed as in A. (E) Western blot analysis of DAPK2 in NB4 shTP73 during ATRA treatment was performed as in C. MWU: *P , 0.05; **P , 0.01; ***P , 0.001. Figure 3 . DAPK2 binds to p73 and regulates its stability and nuclear localization. (A) Co-IP of DAPK2 and p73 isoforms. 293T Cells were transfected with FLAG-tagged DAPK2, together with HA-tagged p73 isoforms or E2F1 (negative control). IP was performed using FLAG antibody immobilized on sepharose beads. HA and FLAG immunoblotting (IB) of pulled-down and flowthrough proteins are shown. (B) 293T Cells were transfected with or without DAPK2 and p73 isoform expression plasmids. Cytoplasmic and nuclear fractions were extracted and subjected to immunoblotting. H3 and a-tubulin expression levels are shown as loading controls for nuclear (N) and cytoplasmic (C) extracts, respectively. (C) Nuclear levels of HA-tagged proteins were normalized to H3 protein and quantified from 3 independent experiments using ImageJ software (NIH). (D and E) 293T Cells were transiently transfected with DAPK2 wild-type (DAPK2_WT), DAPK2 kinase inactive (DAPK2_K52A), or constitutively active DAPK2 (DAPK2_DCAM), together with different p73 isoform expression plasmids. (D) Total lysate immunoblotting, total protein is shown as a loading control. (E) Quantification of HA-tagged proteins from 3 independent experiments was done as in C.
dominant-negative properties that inhibit the corresponding wild-type form [17] . As H1299 cells do not express the p53 protein, we can exclude any nonspecific activity from endogenous p53. TAp73a and -b significantly activated the DAPK2 promoter, whereas the dominant-negative DNp73a and TAp73a_R292H inhibited DAPK2 promoter activity (Fig. 1C) .
Together, our results demonstrate that DAPK2 is transcriptionally regulated by TAp73 isoforms.
p73-dependent induction of DAPK2 during ATO and ATRA therapy Next, we asked whether p73 regulates DAPK2 expression during APL treatment. First, we tested whether ATO (1, 2.5, and 5 mM) or ATRA (1 mM) treatments induced DAPK2 expression in 2 different APL cell line models, NB4 and HT93. As described previously, we confirmed that TAp73 levels increase upon ATO and ATRA treatment of APL cells [41, 43-45] (Supplemental Fig.  2A and D) . Of interest, DAPK2 mRNA (Supplemental Fig. 2B and E) and protein levels (Supplemental Fig. 2C and F) were markedly induced upon ATO, as well as ATRA treatments [33, 34] .
To test if a p73-DAPK2 pathway is relevant in response to ATO or ATRA treatment, we used three independent TP73-targeted shRNAs (shTP73) to decrease TP73 expression in NB4 cells. Knockdown efficiency was confirmed by qPCR using TAp73-specific primers [17] (Fig. 2A) . First, we observed a significant reduction in DAPK2 mRNA and protein levels in all 3 NB4 TP73 knockdown cells ( Fig. 2B and C ; P , 0.05) upon ATO treatment. Importantly, depletion of p73 expression in NB4 cells also attenuated DAPK2 up-regulation upon ATRA-induced neutrophil differentiation ( Fig. 2D and E ; P , 0.01). Together, our results provide evidence that DAPK2 expression levels are positively correlated with TAp73 expression in ATO-and ATRAtreated NB4 APL cells.
A novel DAPK2-p73 protein-protein interaction stabilizes p73 isoforms
Earlier it was found that DAPK1, the closest DAPK2 relative, binds to p53 and modulates its activity [46] . This prompted us to test whether DAPK2 might interact with p73 protein using IP. To this end, we expressed FLAG-tagged DAPK2 together with different HA-tagged p73 isoforms in 293T cells. HA-tagged E2F1 served as a negative control to exclude nonspecific DAPK2 binding to the HA tag. FLAG IP revealed that DAPK2 binds to TA and ΔN a and b p73 isoforms but not to E2F1 (Fig. 3A) , suggesting that DAPK2 binds to the p73 DNA-binding and/or oligomerization domain. Next, we tested if DAPK2 expression influences p73 cellular localization. Therefore, we ectopically expressed the different HA-tagged p73 isoforms together with FLAG-tagged DAPK2 in 293T cells and performed nuclear/ cytoplasmic fractionation followed by Western blotting. We observed that TAp73a, TAp73b, and DNp73a protein levels were increased in the presence of DAPK2 and that the p73 protein isoforms accumulated in the nucleus (Fig. 3B and C) , suggesting that DAPK2 regulates p73 stability, as well as cellular localization. To test if p73 protein stabilization depends on DAPK2 kinase activity, we coexpressed the different p73 isoforms together with wild-type (DAPK2_WT), kinase inactive (DAPK2_K52A), or constitutively active (DAPK2_DCAM) DAPK2. TAp73a, TAp73b, and DNp73a isoform levels were increased in the presence of DAPK2_WT and DAPK2_DCAM but not in the presence of kinase-inactive DAPK2_K52A (Fig. 3D and E) . In summary, our results indicate that kinase-active DAPK2 stabilizes TAp73a, TAp73b, and DNp73a and supports nuclear localization of this transcription factor.
ATO-induced apoptosis in APL cells depends on DAPK2
Successful ATO treatment in AML and multiple myeloma cells depends on functional p73 [45, 47] . Our results suggest that p73 and DAPK2 constitute a positive-feedback loop. Therefore, we asked whether p73-dependent up-regulation of DAPK2 expression upon ATO treatment contributes to the observed cell-death response in APL cells. We confirmed that the knocking down of TP73 significantly impairs ATO-induced apoptosis [44, 47] (Supplemental Fig. 3) . Next, we inhibited DAPK2 expression using two independent shRNA and treated NB4 control and knockdown cells with different concentrations of ATO (1, 2.5, and 5 mM) for 24 h before assessing apoptosis. Knockdown efficiency was verified at the mRNA and protein levels (Fig. 4A) . We found that reduced DAPK2 expression resulted in significantly lower caspase3/7 activity upon ATO treatment compared with control cells (Fig. 4B, upper) . Accordingly, we observed decreased caspase 3 cleavage in both NB4 DAPK2 knockdown cell lines (Fig. 4B, lower) . In addition, we monitored cell viability in NB4 DAPK2 knockdown cells upon ATO treatment using alamarBlue reduction and Trypan blue exclusion assays. The knocking down of DAPK2 resulted in significantly increased NB4 cell viability, further supporting the notion that DAPK2 is needed for ATO-mediated toxicity (Fig. 4C and D) . These data strongly suggest that ATO-induced cell death depends on TAp73 and DAPK2.
DAPK2 depletion attenuates ATRA-but not ATO-induced autophagy
Autophagy activity is critical for the antitumor effect of ATO [48] . Furthermore, DAPK family members not only participate in classic cell death pathways but also contribute to autophagy induction [49] . Of relevance for this study is that overexpression of DAPK2 induces autophagy in 293T HEK cells and in hepatocellular carcinoma [29, 31] . Furthermore, p73 regulates ATG5 and DRAM-1 expression, key regulators of autophagy [21, 22] . In addition, studies showed that autophagy contributes to ATO-and ATRA-induced responses of APL cells by degrading aggregated PML-RARA proteins [9] [10] [11] . These findings prompted us to analyze if DAPK2 and p73 are part of an ATO-or ATRAinduced autophagy pathway in APL cells.
First, to study the impact of DAPK2 and p73 on ATO-induced autophagy in APL cells, we used NB4 TP73 and DAPK2 knockdown cells and treated them with 1 mM ATO for 24 h. Autophagy induction was determined by quantifying endogenous, lipidated LC3B-II by Western blotting and immunofluorescence microscopy [50] . To measure autophagic flux, ATO treatment was done in the presence or absence of the lysosomal inhibitor BafA1 [50] . We found that upon ATO treatment, the autophagic activity was reduced significantly in 2 out of 3 NB4 TP73 knockdown lines compared with the control cells. This is demonstrated by the significantly reduced LC3B-II expression and puncta accumulation in NB4 TP73 knockdown cells (Fig. 5A and C-E) . Importantly, the silencing of DAPK2 did not significantly affect autophagic activity during ATO treatment (Fig. 5B-E) . To confirm our results further, we took advantage of a dual tag mCherry and GFP LC3B expression construct. This marker allows the identification of autolysosomes, as the lower pH in these organelles quenches the green EGFP signal, whereas the red mCherry signal is not affected. Thus, autolysosomes appear red and autophagosomes, yellow based on red and green fluorescence. We quantified autophagic flux using flow cytometry to measure the ratio of mCherry to EGFP fluorescence, as described previously [39] . A threshold, based on control cells, was set to measure the percentage of cells with high autophagic activity, characterized by a high mCherry-height/EGFP-height ratio. Interestingly, the silencing of TP73 but not DAPK2 resulted in a significantly lower percentage of cells with a high autophagic activity in 2 out of 3 TP73 knockdowns compared with control NB4 cells (Fig. 5F and G) . In summary, our data suggest that ATO triggers a p73-dependent but DAPK2-independent autophagy response in NB4 cells.
Next, we performed similar experiments using 1 mM ATRA for 2 d in NB4 cells silenced for DAPK2 or TP73 (Fig. 6A) . As for ATO therapy, knocking down TP73 caused a significant decrease in autophagic activity upon ATRA-mediated differentiation, as evidenced by reduced LC3B dot formation, lower LC3B-II protein levels, and a decreased mCherry/GFP ratio (Fig. 6B, D, E, G, and  H) . Surprisingly, whereas DAPK2 did not significantly impact ATOinduced autophagy, depletion of DAPK2 led to a significant reduction in ATRA-mediated autophagic activity (Fig. 6C, D, F , and H). Together, our data demonstrate that DAPK2, in contrast to ATO therapy, plays a significant role in ATRA-induced autophagy.
ATRA-but not ATO-mediated regulation of ATG5-ATG12 complex formation depends on DAPK2
To confirm our previous data, we measured ATG5-ATG12 complex formation by Western blotting as an additional marker for autophagic activity. Whereas the silencing of DAPK2 knockdown did not affect ATG5-ATG12 complex formation upon ATO treatment (Fig. 7A) , the inhibition of DAPK2 clearly reduced ATG5-ATG12 complex formation compared with control cells upon ATRA treatment (Fig. 7B) . These results further confirm that DAPK2 is part of the ATRA-but not ATO-induced autophagy pathway. Interestingly, the reduced ATG5-ATG12 complex formation did not correlate with low ATG5 mRNA levels (Supplemental Fig. 4) , excluding a block in ATG5 transcription. Next, we speculated that DAPK2 directly participates in ATG5-ATG12 complex formation upon ATRA treatment via direct binding to ATG5; we coexpressed ATG5 together with a FLAG-tagged DAPK2 construct in 293T cells and performed an anti-FLAG pull down. ATG5 protein was coimmunoprecipitated together with DAPK2 (Fig. 7C) , indicating a direct interaction of these two proteins. Then, we repeated the co-IP in NB4 cells stably expressing FLAG-tagged DAPK2 treated for 2 d with ATRA using the anti-FLAG antibody and NB4 control cells expressing the empty vector (CGW) as a negative control. ATG5 immunoblotting revealed binding of endogenous ATG5 to FLAG-tagged DAPK2 protein in NB4 cells (Fig. 7D, left) . Surprisingly, we found similar results in NB4 cells treated with 1 mM ATO for 24 h (Fig. 7D, right) .
Altogether, these results demonstrate that DAPK2 is involved in ATRA-induced autophagy, possibly by facilitating ATG5-ATG12 complex formation. Consequently, DAPK2 may support neutrophil differentiation, among others, by activating autophagy in APL cells. 
DISCUSSION
We previously reported that DAPK2 expression is downregulated in primary AML, particularly in APL, where low expression of its positive transcriptional regulator PU.1 and repression by the APL oncofusion protein PML-RARA contribute to the low DAPK2 levels in this disease [33, 34] . Our present work identifies the tumor suppressor p73 as a novel transcriptional regulator of DAPK2 during ATO and ATRA therapy of APL. This newly positive regulator of DAPK2 is frequently deregulated in AML. For instance, p73 has been reported to be stabilized via recruitment to PML nuclear bodies [51] . As in APL, the oncofusion protein PML-RARA impairs PML activity, low DAPK2 levels in APL might be attributed to the enhanced degradation of p73 [51, 52] . In addition, several reports associated aberrant low expression of the fully active TAp73 and increased levels of the dominant-negative ΔNp73 in APL patients with a decreased response to cytarabine-induced apoptosis, anthracycline-based chemotherapy, and ATRA, as well as increased susceptibility to relapse [53, 54] . In line with our findings that ΔNp73 expression inhibits DAPK2 promoter activity, a high DNTP73/TATP73 ratio in APL may contribute to decreased DAPK2 transcription paralleled by lower response to ATO or ATRA therapy. Lastly, TP73 promoter hypermethylation associated with low TATP73 transcript levels was found in 10-15% of AML patient samples, possibly affecting DAPK2 expression as well [55, 56] . Consistent with these findings, we reported increased DAPK2 expression in AML cell lines upon DNA methyltransferase inhibitor treatment [33] . Therefore, we propose that low DAPK2 levels in AML are, in part, a result of low expression or activity of p73.
Our current data, showing that the inhibition of p73 attenuates apoptosis in response to ATO treatment, are in line with previous findings in NB4 and K562, as well as in newly diagnosed APL patients [54, 57] . We now identified DAPK2 as a key downstream effector of p73 during ATO-induced cell death. In contrast, DAPK2 attenuates extrinsic apoptosis induced by TRAIL via inhibition of death receptor 5 expression [24] . As ATO-induced cell death in leukemic cells occurs, mainly via the intrinsic route of apoptosis [58] , we speculate that the pro-and anti-apoptotic functions of DAPK2 depend on the apoptotic pathway involved, as well as on the cellular context. The anti-leukemic effects of ATO not only depend on its property to activate apoptosis but also autophagy via the MEK/ERK pathway [48] . Although DAPK2 has been linked to autophagy [30, 31], we found that p73 regulates a DAPK2-independent autophagy upon ATO treatment. Our results demonstrate that p73 regulates apoptosis via DAPK2, but different p73-regulated autophagy genes are necessary to induce autophagy upon ATO treatment.
We reported earlier that p73 and DAPK2 are essential for ATRA-mediated neutrophil differentiation of APL cells [23, 34] and that APL differentiation depends on noncanonical autophagy [9-11, 38, 59, 60] . In this study, we now link our previous findings by identifying a novel p73-DAPK2 pathway active in ATRA-mediated myeloid autophagy and required for neutrophil differentiation. Furthermore, we suggest that this ATRAmediated autophagy also includes DAPK2-ATG5 interaction for autophagy activation. Therefore, we propose that DAPK2 is central for autophagy induction during granulocytic differentiation. ATG5 also binds to DAPK2 upon cell death induction by ATO. Similar to other autophagy genes, such as Beclin-1, ATG5 has a pivotal role in autophagy and apoptosis. Calpain-cleaved ATG5 promotes an apoptotic stimuli in response to anticancer drugs, such as etoposide and doxorubicin [61] . Therefore, DAPK2 may also support cell death mechanisms via binding to ATG5, depending on the type of cell-death inducer and cellular context. In addition, ATG5 triggers a mitotic catastrophe in Jurkat cells independently of ATG5-ATG12 complex formation [62] . ATG5 translocates to the nucleus and binds to survivin, leading to chromosomal misalignment and segregation defect without induction of cell death. Altogether, the DAPK2-ATG5 interaction may prevent ATG5 translocation to the nucleus, leading to either ATG5 calpain cleavage upon ATO or ATG5-ATG12 complex formation upon ATRA stimulation.
Our data show that DAPK2 binds to the p73 protein family and dependent on DAPK2 kinase activity, stabilizes p73 protein.
Earlier, it was found that the DAPK2 relative, DAPK1, interacts with p53, via its death domain, to modulate p53 activity [46, 63] . Given that DAPK2 lacks this death domain, yet another DAPK protein domain is involved in p73 binding. Thus, the mechanism-how DAPK2 stabilizes p73 protein-clearly needs further investigations. Nevertheless, we propose that DAPK2-p73 protein binding represents a positive-feedback loop, where the increased p73 levels activate DAPK2 transcription.
In summary, in this study, we detailed the molecular mechanisms of DAPK2 transcriptional regulation and its varying function in cell death and autophagy of APL cells upon ATO or ATRA therapy. We provide clear evidence that DAPK2 induction, in response to both ATRA and autophagy therapy, is p73 dependent. Depending on the applied treatment, DAPK2 is either essential for cell death or autophagy responses (Fig. 8) . Overall, our findings suggest that current APL therapies rely on functional DAPK2 and would benefit from increased activity of this kinase. 
